Related Experiment Video
Updated: Jun 3, 2025
Multi-enzyme Screening Using a High-throughput Genetic Enzyme Screening System
Published on: August 8, 2016
DNAzyme assisted single amplification for FEN1 activity detection using a personal glucose meter
Mingxi Li1, Weijie Zang2, Shuiliang Wang3
1MOE Key Laboratory for Analytical Science of Food Safety and Biology, Fujian Provincial Key Laboratory of Analysis and Detection Technology for Food Safety, College of Chemistry, Fuzhou University, Fuzhou, 350116, PR China; Fujian Key Laboratory of Functional Marine Sensing Materials, Center for Advanced Marine Materials and Smart Sensors, College of Materials and Chemical Engineering, Minjiang University, Fuzhou, 350108, PR China.
A new DNAzyme-based sensing system (Dz-PGM) enables sensitive detection of Flap endonuclease 1 (FEN1), a key cancer biomarker. This point-of-care technology aids in early cancer diagnosis and drug screening.
Area of Science:
- Biochemistry
- Molecular Biology
- Biotechnology
Background:
- Flap endonuclease 1 (FEN1) is crucial in DNA repair and cancer progression.
- FEN1 activity is linked to genomic instability and serves as a cancer biomarker.
- Sensitive detection methods for FEN1 are needed for cancer diagnosis and research.
Purpose of the Study:
- To develop a novel DNAzyme signal amplification-directed point-of-care sensing system (Dz-PGM) for FEN1 detection.
- To establish a sensitive, specific, and versatile platform for FEN1 analysis.
- To explore the utility of the Dz-PGM system in drug screening and clinical sample analysis.
Main Methods:
- Development of a DNAzyme-based sensing system (Dz-PGM) utilizing signal amplification.
- Integration of DNAzyme amplification with a personal glucose meter (PGM) for signal reporting.
- Employing enzymatic recognition, magnetic separation, and biochemical cascades for FEN1 detection.
Main Results:
- The Dz-PGM system achieved high specificity and a low detection limit of 3.56× 10-2 U/mL for FEN1.
- Demonstrated versatility in screening FEN1 inhibitor drugs.
- Accurately distinguished FEN1 levels in real cell samples.
Conclusions:
- The Dz-PGM system offers a promising tool for sensitive and specific FEN1 detection.
- This technology has potential for early cancer diagnosis and developing detection platforms for DNA repair enzymes.
- The system's point-of-care nature facilitates accessible biomarker analysis.
